Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370 | Chief Operating Officer | April 01, 2026 | April 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTUATE THERAPEUTICS, INC.
Report date April 01, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2036-04-01 | Direct | 105,000 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 105,000 · Balance 105,000 F1: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date September 24, 2025 · Filed September 26, 2025
Jointly reported with Tactic Pharma LLC, Robinson Chandler, Brown Michael J, O'Halloran Thomas V.
Section 16 reporting ended · disclosed 2025-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,026 |
Reported balance
After 2025-09-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-09-24 · Sale · Disposed 550,229 · Balance 272,026 F1: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 1, 2026 21:19 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001683168-26-002581 · ownership.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-04-01 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| September 24, 2025 Filed Sep 26, 2025 15:53 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 550,229 | $63.61 | $34,999,956.64 |
DisclosureSEC source: 0001437749-25-029925 · rdgdoc.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer Brown Michael J · CIK 0001035909 · Member of 10% Owner Group O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,026 F1 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 19:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 33,334 | $35.00 | $1,166,690.00 |
DisclosureSEC source: 0001437749-25-011068 · rdgdoc.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer Brown Michael J · CIK 0001035909 · Member of 10% Owner Group O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,255 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:43 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantEmployee Stock Option (right to buy) · Derivative | 110,346 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002210 · ownership.xml · derivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,346 Underlying: Common Stock · 110,346 shares Expires 2035-03-31 F2 · derivative.exercise_date: Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:43 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantEmployee Stock Option (right to buy) · Derivative | 51,046 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002210 · ownership.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,046 Underlying: Common Stock · 51,046 shares Expires 2035-03-31 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-004490 · section16.xml · derivative · entry 5 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,792 Underlying: Common Stock · 1,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 471 | $2.55 | $1,201.05 |
DisclosureSEC source: 0001654954-22-004490 · section16.xml · nonDerivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,124.8 Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-004490 · section16.xml · nonDerivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,595.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 67,251 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001174 · section16.xml · derivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,398 Underlying: Common Stock · 67,251 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 88,874 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001174 · section16.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,874 Underlying: Common Stock · 88,874 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000130 · section16.xml · derivative · entry 5 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,874 Underlying: Common Stock · 1,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 671 | $3.21 | $2,153.91 |
DisclosureSEC source: 0001654954-22-000130 · section16.xml · nonDerivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,989.8 Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000130 · section16.xml · nonDerivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,660.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000129 · section16.xml · derivative · entry 5 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 Underlying: Common Stock · 1,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 556 | $3.21 | $1,784.76 |
DisclosureSEC source: 0001654954-22-000129 · section16.xml · nonDerivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,723.8 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000129 · section16.xml · nonDerivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,279.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010720 · section16.xml · derivative · entry 5 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,879 Underlying: Common Stock · 1,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 471 | $4.87 | $2,293.77 |
DisclosureSEC source: 0001654954-21-010720 · section16.xml · nonDerivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,673.8 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-010720 · section16.xml · nonDerivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,144.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:11 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 3,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007595 · section16.xml · derivative · entry 5 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,485 Underlying: Common Stock · 3,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:11 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 942 | $5.89 | $5,548.38 |
DisclosureSEC source: 0001654954-21-007595 · section16.xml · nonDerivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,538.8 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:11 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 3,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-007595 · section16.xml · nonDerivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,480.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 11,929 | $16.90 | $201,600.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 5 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 16,384 | $16.44 | $269,352.96 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 4 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,596 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 29,996 | $15.12 | $453,539.52 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 3 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,980 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 24,224 | $14.09 | $341,316.16 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 2 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,976 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 42,467 | $13.30 | $564,811.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,200 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 25,697 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000911 · section16.xml · derivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,508 Underlying: Common Stock · 25,697 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024) Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 36,077 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001654954-21-000911 · section16.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,077 Underlying: Common Stock · 36,077 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2021 and 1/48th monthly on the last day of each month thereafter. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000156 · section16.xml · derivative · entry 5 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,811 Underlying: Common Stock · 1,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 671 | $6.12 | $4,106.52 |
DisclosureSEC source: 0001654954-21-000156 · section16.xml · nonDerivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,268.8 Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000156 · section16.xml · nonDerivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,939.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 01:55 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 32,193 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001654954-20-001792 · section16.xml · derivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,193 Underlying: Common Stock · 32,193 shares Expires 2030-01-31 F2 · derivative.exercise_date: Stock options vest 6/48ths on the 6-month anniversary of vesting commencement date of January 1, 2020, and 1/48th per month thereafter Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 01:55 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 7,748 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-001792 · section16.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,748 Underlying: Common Stock · 7,748 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024. F1 · derivative.expiration_date: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 125,000 | $8.00 | $1,000,000.00 |
DisclosureSEC source: 0001654954-19-014150 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer · 10% owner O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,667 F1 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| August 09, 2018 Filed Sep 27, 2018 22:32 UTC | Monopar Therapeutics NONE · Entity 5152 | GrantStock options · Derivative | 134,300 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010573 · section16.xml · derivative · entry 4 Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,300 Underlying: Common stock · 134,300 shares Expires 2028-08-08 F3 · derivative.exercise_date: Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.